Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Royal Marsden NHS Foundation Trust |
---|---|
Information provided by: | Royal Marsden NHS Foundation Trust |
ClinicalTrials.gov Identifier: | NCT00301301 |
There has been considerable international /national interest in the GEM−P regimen for treatment of patients with relapsed/refractory lymphoma. Currently, there is no accepted standard therapy for these patients. Since the publication of our experience with this regimen (Study with CCR ethics number 1857 closed to recruitment in July 2003:Ng M, Waters J, Cunningham D et al, Br J Cancer 2005;92:1352−7), we have treated relapsed/refractory lymphoma patients with this regimen and would like to undertake a retrospective review of a sub−group of these patients with diffuse large B cell lymphoma (DLBCL).
Patients treated with GEM−P with or without Rituximab prior to March 2005 for refractory/relapsed DLBCL will be included in the analysis. Accrual of eligible patients currently under follow−up will be performed in clinic at the time of next appointment.
All patients accrued will give informed consent for retrosepective case note review, after discussion with a study investigator and after receiving a study information sheet. All eligible patients identified from the pharmacy database, and will be consented at the time of the next clinic appointment, if they are agreeable for the retrospective case note review.
Condition | Intervention |
---|---|
Non-Hodgkins Lymphoma |
Drug: Gemcitabine Drug: Cisplatinum Drug: Rituximab |
Study Type: | Observational |
Study Design: | Longitudinal, Defined Population, Retrospective Study |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Contact: Bhawna Sirohi, MBBS, MD | 0044 208 661 3115 | bhawna.sirohi@rmh.nhs.uk |
Contact: Jacqui Oates | 0044 2086613279 | jacqui.oates@rmh.nhs.uk |
United Kingdom, Surrey | |
Royal Marsden NHS trust | Recruiting |
Sutton, Surrey, United Kingdom, SM2 5PT | |
Contact: Bhawna Sirohi, MBBS, MD 0044 208 661 3115 bhawna.sirohi@rmh.nhs.uk | |
Sub-Investigator: Bhawna Sirohi, MBBs, MD |
Principal Investigator: | David Cunningham, FRCP | Royal Marsden NHS Foundation Trust |
Study ID Numbers: | 2656 |
Study First Received: | March 9, 2006 |
Last Updated: | October 12, 2006 |
ClinicalTrials.gov Identifier: | NCT00301301 History of Changes |
Health Authority: | United Kingdom: National Health Service |
Antimetabolites Lymphoma, Large B-Cell, Diffuse Immunoproliferative Disorders Immunologic Factors Rituximab Methylprednisolone Immunosuppressive Agents Antiviral Agents Lymphoma, B-Cell Lymphoma, Small Cleaved-cell, Diffuse |
Lymphatic Diseases Radiation-Sensitizing Agents Cisplatin B-cell Lymphomas Antirheumatic Agents Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Lymphoma, Large-cell Gemcitabine Lymphoma |
Antimetabolites Anti-Infective Agents Antimetabolites, Antineoplastic Immunologic Factors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Physiological Effects of Drugs Lymphoma, B-Cell Cisplatin Therapeutic Uses Gemcitabine Lymphoma Lymphoma, Large B-Cell, Diffuse Immunoproliferative Disorders |
Neoplasms by Histologic Type Immune System Diseases Rituximab Enzyme Inhibitors Antiviral Agents Immunosuppressive Agents Pharmacologic Actions Lymphatic Diseases Neoplasms Radiation-Sensitizing Agents Antirheumatic Agents Lymphoproliferative Disorders Lymphoma, Non-Hodgkin |